Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Aug 7, 2014
NEW HAVEN, Conn., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2014 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of the hepatitis C virus (HCV). For the second quarter ...
PDF
Jul 1, 2014
NEW HAVEN, Conn., July 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that it has been added to the Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Annual reconstitution of Russell's U.S. indexes captures t...
PDF
Jun 11, 2014
NEW HAVEN, Conn., June 11, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences: 2014 Wells Fargo Healthcare Conference on Wednesday, June 18, 2014 at 1:15 p.m. ET at the InterContinental Hotel in ...
PDF
Jun 10, 2014
Initial cohort of HCV-infected patients begin dosing with ACH-3422 for seven daysClinical trials may continue evaluating 200 mg of sovaprevir for HCV-infected patientsTimelines for reporting proof-of-concept results with ACH-3422, a proprietary uridine-analog nucleotide polymerase inhibitor, during the fall of 2014 and initiating all-oral combinati...
PDF
May 7, 2014
NEW HAVEN, Conn., May 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $16.1 million or $0.17 per share, compared with a net loss of $11.7 million or $0.14 per share for the first qua...
PDF
May 1, 2014
NEW HAVEN, Conn., May 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at three upcoming investor conferences: Deutsche Bank Securities 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:10 p.m. ET at the InterCo...
PDF
Apr 30, 2014
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug -- Initiated Phase 2 Study Evaluating ACH-3102, Second-Generation NS5A Inhibitor, With Sofosbuvir for 8 Weeks of Treatment or Less in Genotype 1 HCV Treatment-Naïve Patients - NEW HAVEN, Conn.,...
PDF
Mar 14, 2014
NEW HAVEN, Conn., March 14, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two oral presentations were made at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by ...
PDF
Mar 7, 2014
NEW HAVEN, Conn., March 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013. For the three months ended December 31, 2013, the Company reported a net loss of $13.4 million, compared to a net loss of $11.2 million in the three months en...
PDF
Feb 10, 2014
NEW HAVEN, Conn., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 8:55 a...
PDF
FirstPrevious
...
7
...
NextLast